This method offers significant advantages over traditional approaches: firstly, computer simulations enable rapid screening of thousands of known drugs, significantly shortening the research and development cycle; secondly, these drugs have already passed FDA safety reviews, allowing them to progress directly to clinical validation; most importantly, this technology allows for precise atomic-level analysis of the interaction between drugs and YBX1, providing crucial insights for the development of novel anti-pulmonary fibrosis drugs. This evidence concerns the gene YBX1 and pulmonary fibrosis.